Cargando…
Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State
OBJECTIVES: To investigate the ability of different EuroQol 5-Dimensions 3-Levels (EQ-5D-3L) index scores to discriminate between verum drug and placebo (discriminant validity) as well as between responders and non-responders (known-groups validity) in the SLE patient population of two phase III cli...
Autores principales: | Hua, Nicole, Gomez, Alvaro, Lindblom, Julius, Emamikia, Sharzad, Enman, Yvonne, Grannas, David, Heintz, Emelie, Regardt, Malin, Parodis, Ioannis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691928/ https://www.ncbi.nlm.nih.gov/pubmed/36946293 http://dx.doi.org/10.1093/rheumatology/kead140 |
Ejemplares similares
-
EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2022) -
EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2021) -
Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus
por: Borg, Alexander, et al.
Publicado: (2023) -
Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2021) -
Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE
por: Borg, Alexander, et al.
Publicado: (2021)